Navigation Links
Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 2008

CEDAR KNOLLS, N.J., April 15 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS), announced today that it will host its Annual Stockholders Meeting on Thursday, May 8, 2008, at the Westin Governor Morris, located at Two Whippany Road, Morristown, New Jersey. The meeting will begin at 10:00 a.m. EDT.


Emisphere Technologies, Inc. is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its eligen(R) Technology. These molecules and compounds could be currently available or are in preclinical or clinical development. Such molecules or compounds usually cannot be delivered by the oral route of administration or the benefits of these compounds are limited due to poor bioavailability, slow on-set of action or variable absorption. The eligen(R) Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, per rectum, pulmonary, intra-vaginal or transdermal. The web site is:

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, or Emisphere's ability to fund such efforts with or without partners. Emisphere undertakes no obligation to update any of these statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as to the date hereof. Accordingly any forward-looking statements should be read in conjunction with the additional risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, filed on March 17, 2008, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007, filed on May 7, 2007 (file no. 000-17758), for the quarter ended June 30, 2007, filed on August 7, 2007 (file No. 000-17758), and for the quarter ended September 30, 2007, filed on November 6, 2007 (000-17758).

SOURCE Emisphere Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results
2. Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results
3. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
4. Emisphere Technologies to Present at BIO CEO & Investor Conference on February 12
5. Emisphere to Host Business Strategy Conference Call on February 7
6. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
7. Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology
8. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
9. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
(Date:10/13/2015)... Oct. 13, 2015 PharmaCyte Biotech, Inc. (OTCQB: PMCB) ... volume was at near average with 1,308,352 shares being traded. ... this year hitting a low of $.072 in September, then ... --> Our due diligence will show investors in ... Get our report by using the link below at no ...
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero AG , the ... cell culture models, has launched a 14 Day Hepatotoxicity Testing Service ... Human Liver Microtissues. The service streamlines toxicity testing of compounds in InSphero’s ...
(Date:10/13/2015)... DE (PRWEB) , ... October 13, 2015 , ... ... its new President. Steve joins as the Pistoia Alliance continues to drive to ... , The non-profit Pistoia Alliance is focusing its vision and expanding its work ...
(Date:10/13/2015)... , Oct. 13 2015 Research and ... "US & Europe Markets for Bone Morphogenetic Protein ... to their offering. --> ... that induce the formation of bone after a fracture. ... embryonic development in the formation of the skeleton. There ...
Breaking Biology Technology:
(Date:10/13/2015)... , Oct. 13, 2015 Feedzai ... learning to analyze big data and minimize risk in ... Emailage , an innovative fraud prevention solution that ... risk based on a user,s email address. The two ... learning solution that combines email risk assessment with fraud ...
(Date:10/13/2015)... , October 13, 2015 Dragon ... tech companies in China , announced today ... Limited ("Yazheng"), has received a contract for Multi-Format Naked Eye ... awarded Yazheng approximately $450,000 for the project that is expected ... achieve 30% to 35% in gross profits. ...
(Date:10/13/2015)... , Oct. 7, 2015 Research and ... the "India Biometrics Authentication & Identification Market - ... --> --> ... $823.46 million in 2014 to $2.06 billion in 2020 ... 2020. India . Growing ...
Breaking Biology News(10 mins):